SCHEMBL23749880

SCHEMBL23749880

CCOC(=O)/N=c1\sccn1-c1ccc(Br)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.42
GSK3B P49841 1/20 0.40
MAPT P10636 3/20 0.38
GAA P10253 3/20 0.38
KMT2A Q03164 2/20 0.38
CASP3 P42574 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
HTT P42858 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
NPSR1 Q6W5P4 4/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
S1PR4 O95977 1/20 0.36
S1PR1 P21453 1/20 0.36
MAPK1 P28482 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30130847 0.90 ALDH1A1 (0.43) RXFP1GSK3BMAPTGAAKMT2A
SCHEMBL23749878 0.87 NPC1 (0.44) GSK3BMAPTKMT2ACYP1A2HTT
SCHEMBL23750079 0.87 GSK3B (0.53) RXFP1GSK3BMAPTGAANPSR1
SCHEMBL23750038 0.86 NPC1 (0.47) GSK3BMAPTGAAKMT2ACYP1A2
SCHEMBL30130822 0.86 NPC1 (0.47) GSK3BMAPTGAAKMT2ACYP1A2
SCHEMBL23749746 0.81 GSK3B (0.36) RXFP1GSK3BGAANPSR1MAPK1
SCHEMBL30130791 0.80 RAB9A (0.42) RXFP1GSK3BKMT2AHTTNPSR1
SCHEMBL30136177 0.80 GSK3B (0.44) RXFP1GSK3BMAPTGAAHTT
SCHEMBL23749905 0.80 GSK3B (0.44) RXFP1GSK3BMAPTGAAHTT
SCHEMBL23727748 0.79 PKM (0.38) MAPTGAAKMT2AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss THE ROCKEFELLER UNIVERSITY (US) 2026-05-05 US disclosed
EP-4100008-B1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS UNIV ROCKEFELLER (US) 2025-04-02 EP disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
CN-115515579-A Pyrrolo [2,3-b ] pyridine-3-carboxamide compositions and methods for ameliorating hearing loss 洛克菲勒大学 2022-12-23 CN disclosed
EP-4100008-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS The Rockefeller University (US) 2022-12-14 EP disclosed
WO-2021158936-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss YAP1, LATS2, LATS1 RXFP1 2841/4885GSK3B 606/4885MAPT 4154/4885
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS LATS2, LATS1, YAP1 RXFP1 2806/4885GSK3B 516/4885MAPT 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.